NEXTPro: Next Generation Radioligand Therapy for Prostate Cancer

• Unité de recherche: INNOSUISSE
• Numéro de projet: 134.816 IP-LS
• Titre du projet anglais: NEXTPro: Next Generation Radioligand Therapy for Prostate Cancer

Mots-clé (Anglais)

Life sciences, Personalised medicine

Résumé des résultats (Abstract) (Anglais)

NEXTPro develops a 177Lu-based radioligand therapy targeting prostatic acid phosphatase (PAP) for prostate cancer patients not responding to PSMA therapies. The project validates the lead candidate NEXTPro-131 through translational biodistribution, dosimetry, efficacy, and safety studies.